Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|March 18, 2025
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic reviewYing Wu, Zhenpeng Zeng, Shuanggang Chen, et al.
Journal of Cancer Research and Therapeutics|June 4, 2026
Thermal ablation versus hepatectomy in patients with liver metastases from RAS-mutated colorectal cancerChunyong Wen, Changqing Zhou, Shuanggang Chen, et al.
Aging|November 5, 2019
Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasionFei Cao, Lujun Shen, Han Qi, et al.
Cancer Management and Research|December 6, 2019
Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching AnalysisZhiyu Qiu, Lujun Shen, Shuanggang Chen, et al.
Thoracic Cancer|April 26, 2019
Safety and efficacy of thermal ablation for subpleural lung cancersFei Cao, Lin Xie, Han Qi, et al.
Frontiers in Oncology|October 12, 2020
Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of AblationShuanggang Chen, Weimei Ma, Fei Cao, et al.
The British Journal of Radiology|June 8, 2026
CT-guided microwave ablation for large inoperable pulmonary metastases from sarcoma: a case seriesLin Xie, Fei Cao, Lujun Shen, et al.
Frontiers in Oncology|November 4, 2021
Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and AblationShuanggang Chen, Weimei Ma, Lujun Shen, et al.
Thoracic Cancer|April 25, 2019
Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablationFei Cao, Chao Wan, Lin Xie, et al.
BMJ Open Gastroenterology|May 5, 2026
Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy eraShuanggang Chen, Lujun Shen, Han Qi, et al.
Pageof 4